Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BDX

Becton Dickinson Buying Parata Systems - Read Why

Becton Dickinson and Co (NYSE:BDX) will acquire Parata Systems from Frazier Healthcare Partners for $1.525 billion. Parata offers a portfolio of pharmacy automation solutions to reduce costs, enhance patient safety and improve the patient experience. Significant macro trends such as clinician shortages, wage inflation, centralization of pharmacy services, and increased clinical demands…

$1000 Invested In Becton, Dickinson 10 Years Ago Would Be Worth This Much

$1000 Invested In Becton, Dickinson 10 Years Ago Would Be Worth This Much

Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 10 years by 1.48% on an annualized basis producing an average annual return of 13.59%. Currently, Becton, Dickinson has a market capitalization of $72.68 billion.

Better Buy: Becton Dickinson vs. Intuitive Surgical

Better Buy: Becton Dickinson vs. Intuitive Surgical

Growing demand for critical surgical procedures and increasing investments in R&D should drive the medical devices industry’s growth. Prominent medical device companies Becton Dickinson (BDX) and Intuitive Surgical (ISRG) are well-positioned to capitalize on the industry tailwinds. But which of these stocks is a better buy now? Read more to…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Are Medical Device Stocks Good Investments During a Recession?

The stock market has witnessed a massive sell-off lately on concerns over the Fed’s aggressive interest rate hikes to fight the decade-high inflation. Many analysts expect the economy to slip into recession due to the Fed’s monetary policy tightening. Since the medical device industry is known to be one of…

Becton Dickinson Raises FY22 Guidance As Q2 Earnings Top Estimates

Becton Dickinson and Co (NYSE:BDX) reported Q2 FY22 revenues of $5.01 billion, up 2.1% Y/Y (3.9% on a currency-neutral basis), better than the consensus of $4.85 billion. Revenue was driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by the decline in COVID-only testing revenues to $214 million…

5 Safe-Haven Dividend Stocks to Add to Your Portfolio

Deepening logistical disruptions caused by the Russia-Ukraine war, record-high inflation, and high oil prices have dampened investor sentiment. Furthermore, many economists expect the economy to succumb to a recession, with inflation hitting a fresh 40-year high and oil prices soaring. Therefore, we think it could be wise to bet on…

Buy These 5 Defensive Stocks to Protect Your Portfolio from Market Volatility

Defensive stocks are known for exhibiting stability during wild price swings in the market. And growing sanctions on Russia and the unstable nature of crude oil prices may drive further volatility in the market. So, we think it could be wise to bet now on defensive stocks CVS Health (CVS),…

inkl

Read news from The Economist, FT, and more,
with one subscription

5 Stocks to Buy for Stable Income in a Volatile Market

5 Stocks to Buy for Stable Income in a Volatile Market

Because concerns over high inflation and increasing sanctions on Russia are expected to fuel stock market volatility in the near term, we think it could be wise to bet on dividend aristocrats Johnson & Johnson (JNJ), Procter & Gamble (PG), PepsiCo (PEP), Abbott (ABT), and Becton Dickinson (BDX) for a…

4 Red-Hot Value Stocks to Buy This Month

4 Red-Hot Value Stocks to Buy This Month

Investing in fundamentally sound value stocks could be ideal amid surging market volatility, which is due to the rising interest rates, heightened inflation, supply chain disruptions, and an escalating war between Russia and Ukraine. Thus, we think the shares of industry leaders Bristol-Myers (BMY), Lockheed Martin (LMT), Becton Dickinson (BDX),…

Becton Dickinson Q1 Earnings Top Estimates, Raises FY22 Guidance On Higher COVID-19 Related Sales

Becton Dickinson Q1 Earnings Top Estimates, Raises FY22 Guidance On Higher COVID-19 Related Sales

Becton Dickinson and Co (NYSE: BDX) reported Q1 FY22 revenues of $4.9 billion, down 6% Y/Y (-5.9% on a currency-neutral basis), better than the consensus of $4.76 billion.

Becton Dickinson Strengthens Post-Treatment Monitoring For Blood Cancers With Cytognos Acquisition

Becton Dickinson Strengthens Post-Treatment Monitoring For Blood Cancers With Cytognos Acquisition

Becton, Dickinson and Co (NYSE: BDX) has acquired Cytognos, a unit of Vitro SA, a Spanish diagnostics company that develops, produces, and sells fully integrated reagents, hardware, and software platforms.

Baxter International vs. Becton Dickinson: Which Medical Equipment & Supply Stock is a Better Buy?

Baxter International vs. Becton Dickinson: Which Medical Equipment & Supply Stock is a Better Buy?

The demand for medical equipment & supplies is rising exponentially with the emergence of severe illnesses such as the ongoing Coronavirus pandemic and the growing elderly population. So, Baxter International (BAX) and Becton Dickinson and Company (BDX) should benefit. But which of these two stocks is a better buy now?…

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Johnson & Johnson (

Intuitive Surgical

Target Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Monetary Policy

Places

347,639 stories

133,072 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play